Ten Years Later: Jesse Gelsinger’s Death and Human Subjects Protection
By Osagie K. Obasogie,
Bioethics Forum
| 10. 22. 2009
Last month marked the tenth anniversary of Jesse Gelsinger's death. While perhaps not quite a household name, Gelsinger is vividly remembered among many medical researchers. His death during a gene therapy clinical trial in September 1999 rocked the field like nothing else since the Tuskegee experiments. But sadly, the questionable research practices that led to Gelsinger's death have only become more troublesome in the past decade. Indeed, protections for clinical trial participants seem to be waning at the very moment they are needed most.
Gelsinger suffered from orinthine trascarbamlase deficiency (OTCD), a rare metabolic disorder that prevents the body from breaking down ammonia. Many children with OTCD die at a young age, but Gelsinger had a mild version and led a fairly normal life through medicine and a special diet. Since a single-gene defect is responsible for OTCD, researchers considered it a prime candidate for gene therapy, a still-experimental treatment that attempts to replace defective genes with normal ones.
Gene therapy was the embryonic stem cell research of the 1990s; its ability to cure was thought to be boundless and... see more
Related Articles
By Gina Maranto, Biopolitical Times guest contributor
| 04.05.2021
It’s not for nothing that Time, Inc. developed its formula for telling stories—catchy lede, billboard that tells 'em what you’re going to tell ‘em, last graf that catapults them into the future. No wobbling; narrative charging right along. In the rush, the reader is propelled, questions cast aside, riding the tale you want them to believe.
Not surprisingly, Walter Isaacson, bestselling author and former Time editor, has the style down pat. A sometimes breathless, technocratic enthusiasm; an ability to reduce...
At least five separate studies involving human embryo research are raising fresh versions of old questions about science, ethics and regulation. On March 17, Nature published two peer-reviewed papers about generating in vitro, with slightly different methods, “blastoids” or “human blastocyst-like structures.” (One team, perhaps trying to be cute, called them “iBlastoids” but the Nature summary article sensibly eschews this.) One process involved developing from human embryonic stem cells, the other used cells reprogrammed from adult tissues. A few...
By Antonio Regalado, MIT Technology Review | 03.17.2021
The photographs alone tell a fantastic story—a mouse embryo, complete with beating heart cells, a head, and the beginning of limbs, alive and growing in a glass jar.
According to a scientific group in Israel, which took the picture, the...
By Kashmir Hill, The New York Times | 03.18.2021
Photo by Dan Nelson on Unsplash
In May 2019, an agent at the Department of Homeland Security received a trove of unsettling images. Found by Yahoo in a Syrian user’s account, the photos seemed to document the sexual abuse of...